LU92195I2 - Aflibercept (EYLEA-ZALTRAP) - Google Patents

Aflibercept (EYLEA-ZALTRAP)

Info

Publication number
LU92195I2
LU92195I2 LU92195C LU92195C LU92195I2 LU 92195 I2 LU92195 I2 LU 92195I2 LU 92195 C LU92195 C LU 92195C LU 92195 C LU92195 C LU 92195C LU 92195 I2 LU92195 I2 LU 92195I2
Authority
LU
Luxembourg
Prior art keywords
zaltrap
eylea
aflibercept
macular degeneration
diabetic retinopathy
Prior art date
Application number
LU92195C
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92195(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of LU92195I2 publication Critical patent/LU92195I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
LU92195C 1999-06-08 2013-05-14 Aflibercept (EYLEA-ZALTRAP) LU92195I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08

Publications (1)

Publication Number Publication Date
LU92195I2 true LU92195I2 (fr) 2013-07-15

Family

ID=22480568

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92195C LU92195I2 (fr) 1999-06-08 2013-05-14 Aflibercept (EYLEA-ZALTRAP)

Country Status (32)

Country Link
EP (2) EP1544299B1 (fr)
JP (2) JP4723140B2 (fr)
KR (1) KR100659477B1 (fr)
CN (3) CN100523187C (fr)
AT (2) ATE417928T1 (fr)
AU (2) AU779303B2 (fr)
BE (1) BE2013C029I2 (fr)
BR (2) BR0011407A (fr)
CA (1) CA2376379C (fr)
CY (2) CY1108883T1 (fr)
CZ (2) CZ303656B6 (fr)
DE (2) DE60019415T2 (fr)
DK (2) DK1183353T3 (fr)
ES (2) ES2319305T3 (fr)
FR (1) FR13C0028I2 (fr)
HR (1) HRP20010908B1 (fr)
HU (3) HU230159B1 (fr)
IL (3) IL146890A0 (fr)
LT (1) LTC1183353I2 (fr)
LU (1) LU92195I2 (fr)
ME (2) MEP3208A (fr)
MX (1) MXPA01012630A (fr)
NO (4) NO330775B1 (fr)
NZ (1) NZ515913A (fr)
PL (1) PL208247B1 (fr)
PT (2) PT1183353E (fr)
RS (1) RS50073B (fr)
RU (1) RU2265661C2 (fr)
SK (1) SK287332B6 (fr)
UA (1) UA74146C2 (fr)
WO (1) WO2000075319A1 (fr)
ZA (1) ZA200110068B (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
WO2002060950A2 (fr) 1994-11-14 2002-08-08 Ludwig Institute For Cancer Research Flt4 (vegfr-3) utilise comme cible pour l'imagerie des tumeurs et le traitement antitumoral
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
EP1575548B1 (fr) 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Compositions et methodes visant a favoriser l'excroissance neuronale
PT1608685E (pt) * 2003-03-28 2007-05-31 Regeneron Pharma Anatagonistas de vegf para o tratamento de diabetes.
US8906363B2 (en) 2003-05-16 2014-12-09 Acorda Therapeutics, Inc. Fusion proteins for the treatment of CNS
EP1646353A4 (fr) * 2003-05-16 2008-06-04 Acorda Therapeutics Inc Proteines de fusion destinees au traitement du systeme nerveux central
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
CA2519835A1 (fr) * 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Methode de traitement d'un rejet de keratoplastie
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
CA2519875C (fr) 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Methode favorisant la regression de tumeurs au moyen d'inhibiteurs du vegf (facteur de croissance de l'endothelium vasculaire)
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US20050112061A1 (en) * 2003-08-06 2005-05-26 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
WO2005112986A2 (fr) 2004-05-18 2005-12-01 Acorda Therapeutics, Inc. Procedes de purification de la chondroitinase et formulations stables de cette derniere
KR100897379B1 (ko) * 2004-06-08 2009-05-14 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 혈관신생-저해 키메릭 단백질 및 그 사용
JP2008502738A (ja) 2004-06-10 2008-01-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用
MXPA06014689A (es) * 2004-06-18 2008-03-11 Regeneron Pharma Inhibidores del vegf para el tratamiento de efusion pleural maligna.
MX2007001241A (es) * 2004-07-30 2007-07-11 Regeneron Pharma Metodos para tratar diabetes tipo i mediante el bloqueo de la actividad mediada de vegf.
ATE470454T1 (de) 2004-09-13 2010-06-15 Genzyme Corp Multimere konstrukte
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
EP1877438A2 (fr) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Methode de traitement de lesion oculaire par l'administration locale d'un inhibiteur de vegf
EP2586459B1 (fr) 2005-03-25 2017-05-24 Regeneron Pharmaceuticals, Inc. Formulations antagonistes du VEGF
US7485295B2 (en) 2005-09-26 2009-02-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
JP5489465B2 (ja) † 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
EP3753548A1 (fr) 2006-06-16 2020-12-23 Regeneron Pharmaceuticals, Inc. Formulations antagonistes vegf appropriées pour l'administration intravitréenne
CA2664738C (fr) 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions et procedes permettant de diagnostiquer et de traiter le cancer
EP2079835B1 (fr) 2006-10-10 2014-03-26 Acorda Therapeutics, Inc. Compositions et procédés d'utilisation de mutants des chondroïtinases abci
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
EP2358746B1 (fr) 2008-11-03 2020-09-16 Molecular Partners AG Protéines de liaison inhibant l'interaction du récepteur vegf-a
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
DK2601214T3 (en) 2010-08-06 2018-02-05 Genzyme Corp VEGF ANTAGONIST COMPOSITIONS AND APPLICATIONS THEREOF
WO2012093704A1 (fr) * 2011-01-07 2012-07-12 中外製薬株式会社 Procédé pour l'amélioration de propriétés physiques d'anticorps
KR20200077622A (ko) 2011-01-13 2020-06-30 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
WO2013169614A1 (fr) 2012-05-07 2013-11-14 Allergan, Inc. Procédé de traitement d'amd chez des patients souffrant d'un état réfractaire à la thérapie anti-vegf
WO2014006113A1 (fr) 2012-07-03 2014-01-09 Sanofi Procédé de traitement du cancer par quantités efficaces d'aflibercept
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
SMT202000088T1 (it) 2013-02-18 2020-03-13 Vegenics Pty Ltd Molecole leganti ligandi e relativi usi
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
EP3628324A1 (fr) 2013-11-05 2020-04-01 Allergan, Inc. Procédé de traitement d'états de santé de l' il par un darpin anti-vegf
EP3828202A1 (fr) 2014-05-12 2021-06-02 Formycon AG Seringue en plastique préremplie contenant un antagoniste de vegf
MA40354A (fr) 2014-07-18 2017-05-24 Sanofi Sa Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
SI3230316T1 (sl) 2014-12-11 2022-05-31 Bayer Healthcare Llc Zdravljenje starostne degeneracije makule z majhno aktivno horoidalno neovaskularizacijsko lezijo
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TWI899515B (zh) 2015-08-04 2025-10-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017046140A1 (fr) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Régimes de traitement de dr et rvo en fonction de l'étendue de l'ischémie rétinienne
WO2017065559A1 (fr) 2015-10-15 2017-04-20 (주)알테오젠 Procédé de production de protéine de fusion présentant un domaine fc d'igg
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2018218013A2 (fr) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Conditionnement pharmaceutique stérilisable pour formulations ophtalmiques
US20180326126A1 (en) 2015-11-18 2018-11-15 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
RU2751510C2 (ru) 2015-11-18 2021-07-14 Сио2 Медикал Продактс, Инк. Фармацевтическая упаковка для офтальмологических составов
CN108883172A (zh) 2015-11-18 2018-11-23 福迈康股份公司 包含vegf拮抗剂的液体配制品的预填充药物包装
EP3377101A4 (fr) * 2015-11-19 2019-08-07 Zhuhai Tairuishang Biopharm Ltd. Méthodes et compositions de liaison de vegf
CN114712497B (zh) 2015-12-03 2024-03-22 雷杰纳荣制药公司 抗vegf剂在制备用于治疗新生血管性年龄相关性黄斑变性患者的药物中的用途
AU2017213103B2 (en) 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
JPWO2018070390A1 (ja) 2016-10-12 2019-08-22 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
EP3541365A1 (fr) 2016-11-21 2019-09-25 Just Biotherapeutics, Inc. Formulations d'aflibercecept et leurs utilisations
WO2018217995A1 (fr) 2017-05-24 2018-11-29 Formycon Ag Conditionnements pharmaceutiques pré-remplis stérilisables comprenant une formulation liquide d'un antagoniste du vegf
WO2018215580A1 (fr) 2017-05-24 2018-11-29 Formycon Ag Procédé de stérilisation de seringues en plastique pré-remplies contenant un antagoniste du vegf
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (fr) 2017-07-26 2019-01-31 Formycon Ag Formulation liquide d'un antagoniste du vegf
KR102578087B1 (ko) 2017-08-17 2023-09-18 저스트-에보텍 바이오로직스, 아이엔씨. 숙주세포 갈렉틴(galectins) 및 다른 오염물(contaminant)로부터 글리코실화 단백질을 정제하는 방법
WO2019099965A1 (fr) 2017-11-20 2019-05-23 Just Biotherapeutics, Inc. Formulations d'aflibercept contenant un sel de lysine en tant qu'agent de tonicification et leurs utilisations
FI3717636T3 (fi) 2017-11-27 2023-06-01 4D Molecular Therapeutics Inc Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä
IL274711B2 (en) * 2017-11-30 2024-10-01 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
WO2019118187A1 (fr) * 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Dispositifs et systèmes de gestion de supports de lit de colonne de chromatographie et procédés associés
JP7692699B2 (ja) 2017-12-22 2025-06-16 サムスン バイオエピス カンパニー リミテッド Ｖｅｇｆアンタゴニストを含む液体組成物
EP4495136A3 (fr) 2018-01-26 2025-04-23 The Regents of the University of California Méthodes et compositions pour le traitement de troubles angiogéniques à l'aide d'agents anti-vegf
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
SG11202010684YA (en) 2018-05-10 2020-11-27 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
TW202016125A (zh) * 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
US20220204920A1 (en) 2019-05-16 2022-06-30 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
WO2021046070A1 (fr) 2019-09-03 2021-03-11 Amgen Inc. Dispositif d'injection destiné à l'administration de médicament et emballage destiné au dispositif d'injection
CA3150482A1 (fr) 2019-09-16 2021-03-25 Amgen Inc. Methode de sterilisation externe d'un dispositif d'administration de medicament
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular
KR20220110555A (ko) 2019-12-06 2022-08-08 리제너론 파마슈티칼스 인코포레이티드 Vegf 미니-트랩 및 그의 사용 방법
EP3931303A1 (fr) 2019-12-06 2022-01-05 Regeneron Pharmaceuticals, Inc. Compositions de protéines anti-vegf et leurs procédés de production
US12240652B2 (en) 2020-02-24 2025-03-04 Amgen Inc. Containers and systems for use during external sterilization of drug delivery devices
WO2021226444A2 (fr) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Pièges et mini-pièges de vegf et procédés de traitement de troubles oculaires et de cancers
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
EP4145456A1 (fr) 2021-09-06 2023-03-08 Bayer AG Prédiction d'un changement relatif à un fluide maculaire
WO2023092324A1 (fr) 2021-11-24 2023-06-01 苏州光度生物科技有限公司 Molécule de liaison de ligand multispécifique et son utilisation
CN119677771A (zh) * 2022-08-02 2025-03-21 帕诺洛斯生物科技有限公司 经修饰的融合蛋白及其用途
TW202412840A (zh) 2022-09-16 2024-04-01 大陸商齊魯製藥有限公司 一種穩定的高濃度自緩衝藥物組合物
WO2025033876A1 (fr) * 2023-08-04 2025-02-13 주식회사 파노로스바이오사이언스 Conjugué protéine de fusion modifiée-scfv et son utilisation
WO2025213011A1 (fr) 2024-04-05 2025-10-09 Amgen Inc. Procédé d'évaluation du mouvement d'un bouchon dans un dispositif d'administration de médicament

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
MEP3208A (xx) 2010-02-10
EP1544299B1 (fr) 2008-12-17
KR100659477B1 (ko) 2006-12-20
CZ303656B6 (cs) 2013-01-30
NO2013010I2 (no) 2013-05-15
FR13C0028I1 (fr) 2013-06-14
HK1132653A1 (en) 2010-03-05
NO332559B1 (no) 2012-10-29
JP2011024595A (ja) 2011-02-10
CZ302689B6 (cs) 2011-09-07
CN101433715B (zh) 2013-04-17
CN1369009A (zh) 2002-09-11
BR0011407A (pt) 2002-04-02
YU86901A (sh) 2004-05-12
HRP20010908B1 (en) 2006-05-31
NO2013010I1 (no) 2013-06-17
CA2376379A1 (fr) 2000-12-14
FR13C0028I2 (fr) 2014-05-16
BE2013C029I2 (fr) 2019-03-06
MXPA01012630A (es) 2002-07-22
HUP0201515A2 (en) 2002-08-28
AU2005201365A1 (en) 2005-04-28
NO330775B1 (no) 2011-07-11
CN101433715A (zh) 2009-05-20
BRPI0011407B1 (pt) 2018-09-25
DE60019415D1 (de) 2005-05-19
NZ515913A (en) 2004-01-30
HRP20010908A2 (en) 2005-04-30
ME00024B (fr) 2010-02-10
ZA200110068B (en) 2002-12-06
SK17522001A3 (sk) 2003-04-01
ATE293164T1 (de) 2005-04-15
LTC1183353I2 (lt) 2023-02-27
PL208247B1 (pl) 2011-04-29
EP1183353A1 (fr) 2002-03-06
PT1544299E (pt) 2009-03-18
ES2237429T3 (es) 2005-08-01
ATE417928T1 (de) 2009-01-15
IL146890A (en) 2008-07-08
CN103349781B (zh) 2015-04-01
DE60019415T2 (de) 2006-03-09
PL352246A1 (en) 2003-08-11
UA74146C2 (uk) 2005-11-15
LTPA2013009I1 (lt) 2013-06-25
JP4723140B2 (ja) 2011-07-13
BRPI0011407B8 (pt) 2021-05-25
EP1544299A1 (fr) 2005-06-22
DK1544299T3 (da) 2009-03-23
WO2000075319A1 (fr) 2000-12-14
NO20016036L (no) 2002-02-08
AU779303B2 (en) 2005-01-13
NO2022060I1 (no) 2022-12-21
CY2013019I1 (el) 2015-11-04
RU2265661C2 (ru) 2005-12-10
AU2005201365B2 (en) 2007-08-09
CZ20014387A3 (cs) 2002-10-16
CN100523187C (zh) 2009-08-05
KR20020019070A (ko) 2002-03-09
CY2013019I2 (el) 2015-11-04
NO20016036D0 (no) 2001-12-10
RS50073B (sr) 2009-01-22
CY1108883T1 (el) 2014-07-02
HU229156B1 (en) 2013-09-30
DE60041159D1 (de) 2009-01-29
IL146890A0 (en) 2002-08-14
HUP0201515A3 (en) 2004-12-28
AU5040400A (en) 2000-12-28
DK1183353T3 (da) 2005-08-08
NO20100656L (no) 2002-02-08
HUS1300052I1 (hu) 2016-08-29
CN103349781A (zh) 2013-10-16
JP5273746B2 (ja) 2013-08-28
PT1183353E (pt) 2005-06-30
ES2319305T3 (es) 2009-05-06
SK287332B6 (sk) 2010-07-07
EP1183353B1 (fr) 2005-04-13
IL190234A0 (en) 2008-11-03
HK1043388A1 (en) 2002-09-13
HK1185798A1 (en) 2014-02-28
JP2003501089A (ja) 2003-01-14
CA2376379C (fr) 2007-08-07
HU230159B1 (hu) 2015-09-28

Similar Documents

Publication Publication Date Title
LU92195I2 (fr) Aflibercept (EYLEA-ZALTRAP)
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
ATE396738T1 (de) Verwendung von glp-2-peptiden
DE60137876D1 (de) Analoge des Glucagon-ähnlichen Peptids-1
DE60118921D1 (de) Verfahren und Zusammensetzungen unter Verwendung von Chinazolinonen
BR0016681B1 (pt) composição amaciante de tecidos, e, método de tratamento de tecido.
NO20012160L (no) Anordning for behandling av makuladegenerasjon
DE60136272D1 (de) Diagnostika und therapeutika für makula degeneration erkrankungen
TR200100754T2 (tr) Glausomanın tedavi edilmesi için serotonerjik 5HT2.
NO992916L (no) Fosfodiesterase 8A
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
WO2005051289A3 (fr) Preparations homogenes de proteines chimeres
DE60130798D1 (de) "alpha1-untereinheit des natriumkanals, polypeptide davon und deren verwendung zur behandlung von generalisierter epilepsie mit fieberanfällen plus "
ATE319819T1 (de) Humane hirn-spezifische carboxypeptidase b
PL336764A1 (en) Application 5-(4-(2-(n-methyl-n- (2-pyridylamino)ethoxy)benzyl) -2,4-triazolydinone in treating polycystic ovary syndrome as well as gestational diabetes
PT916670E (pt) Pirrolo-(3,2-b) piridinas e o seu uso como agonistas do 5-ht1f
TR199501276A2 (tr) Sübstitüe edilmis sikloalkilamino-ve-alkoksi-heterosaykillar, üretilmelerine mahsus usul ve zararlilarla mücadele maddesi olarak kullanilmalari.
EP1191096A4 (fr) Nouvelle proteine et son adn
DE59809480D1 (de) Traggerüst für eine oszillierende Kokille
BR9909473B1 (pt) composição herbicida, e, processo para controlar ervas daninhas.